Esophageal Cancer Clinical Trial
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
Summary
The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Overall Survival (OS) and Event-free Survival (EFS) in:
participants with esophageal squamous cell carcinoma (ESCC),
participants whose tumors express Programmed Death-Ligand 1 (immunotherapy-drugs-are-boosting-survival/" >PD-L1) Combined Positive Score (CPS) ≥10, and
all participants.
The primary study hypotheses are that dCRT+ pembrolizumab is better than dCRT + placebo with respect to:
OS in participants with ESCC,
OS in participants whose tumors express PD-L1 CPS ≥10,
OS in all participants,
EFS in participants with ESCC,
EFS in participants whose tumors express PD-L1 CPS ≥10, and
EFS in all participants.
Full Description
Participants receive pembrolizumab or placebo PLUS one of two chemotherapy regimens PLUS radiation therapy for up to approximately one year. The chemotherapy regimens are either:
FP (5-fluorouracil [5-FU] + cisplatin) or
FOLFOX (5-FU + oxaliplatin + leucovorin or levoleucovorin).
Eligibility Criteria
Inclusion Criteria:
Has histologically or cytologically confirmed diagnosis of CTX N+ M0 or cT2-T4a NX M0 ESCC, GEJC, EAC, or histologically or cytologically confirmed diagnosis of cTX N+ M1 cervical or upper thoracic esophageal carcinoma with supraclavicular lymph node metastases only
Is deemed suitable for dCRT
Is ineligible for curative surgery based on the documented opinion of a qualified medical/surgical/radiation oncologist.
Is not expected to require tumor resection during the course of the study
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 3 days of the first dose of study treatment.
Has adequate organ function.
Male participants must use adequate contraception (a male condom plus partner use of an additional contraceptive method) unless confirmed to be azoospermic (vasectomized or secondary to medical cause) and refrain from donating sperm during the study treatment period and through 90 days after the last dose of chemotherapy.
Female participants who are a Woman of Childbearing Potential (WOCBP) must use contraception that is highly effective (with a failure rate of <1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle, during the study treatment period through 180 days after the last dose of chemotherapy or 120 days after the last dose of pembrolizumab, whichever is greater, and agree not to donate eggs to others or freeze/store for her own use for the purpose of reproduction during this period
Female participants must not be pregnant or breastfeeding
Exclusion Criteria:
Has direct invasion of tumor into adjacent organs such as the aorta or trachea or has radiographic evidence of >90 degree encasement or invasion of a major blood vessel, or of intratumoral cavitation.
Has had major surgery other than for insertion of a feeding tube, open biopsy, or significant traumatic injury within 28 days prior to randomization, or anticipates the need for major surgery during study treatment; participants with gastric or esophageal fistulae are excluded
Has had weight loss of >20% in the previous 3 months
Has had prior chemotherapy or radiotherapy for esophageal cancer
Has had a myocardial infarction within the past 6 months
Has symptomatic congestive heart failure
Has received prior therapy with an anti-programmed cell death-1 (anti PD-1), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-programmed cell death-ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX-40, CD137)
Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention; administration of killed vaccines is allowed
Has received any prior systemic anticancer therapy for esophageal cancer including investigational agents
Has not recovered from all adverse events (AEs) due to previous non-anticancer therapies to ≤Grade 1 or Baseline
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment
Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded from the study. Participants with localized prostate cancer that has undergone potentially curative treatment can be enrolled in the study.
Has severe hypersensitivity (≥Grade 3) to pembrolizumab, any of the study chemotherapy agents, or their excipients
Has an active autoimmune disease that has required systemic treatment in past 2 years
Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
Has an active infection requiring systemic therapy
Has a known history of human immunodeficiency virus (HIV) infection
Has a known history of Hepatitis B or known active Hepatitis C virus infection
Has a known history of active tuberculosis (TB; Bacillus tuberculosis)
Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment (180 days for participants receiving cisplatin who are breastfeeding)
Has had an allogenic tissue/solid organ transplant
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 153 Locations for this study
Long Beach California, 90806, United States More Info
Columbia Missouri, 65212, United States
New Brunswick New Jersey, 08901, United States More Info
Portland Oregon, 97239, United States More Info
Spokane Valley Washington, 99216, United States
Madison Wisconsin, 53792, United States More Info
Buenos Aires , C1264, Argentina More Info
Ijui Rio Grande Do Sul, 98700, Brazil More Info
Porto Alegre Rio Grande Do Sul, 91350, Brazil More Info
Montreal Quebec, H2X 0, Canada More Info
Temuco Araucania, 48102, Chile More Info
Santiago Region M. De Santiago, 83300, Chile More Info
Hefei Anhui, 23007, China More Info
Fuzhou Fujian, 35002, China More Info
Xiamen Fujian, 36100, China More Info
Huai An Jiangsu, 22300, China
Xuzhou Jiangsu, 22100, China More Info
Zhenjiang Jiangsu, 21200, China
Tianjin Tianjin, 30006, China More Info
Saint-Cloud Hauts-de-Seine, 92210, France More Info
Stuttgart Baden-Wurttemberg, 70199, Germany More Info
Mainz Rheinland-Pfalz, 55131, Germany More Info
Guatemala , 01010, Guatemala More Info
Guatemala , 01010, Guatemala
Quetzaltenango , 09002, Guatemala More Info
Hong Kong , , Hong Kong
Hong Kong , , Hong Kong
Gyula Bekes, 5700, Hungary
Pavia Lombardia, 27100, Italy More Info
San Donato Milanese Milano, 20097, Italy
Pisa Toscana, 56126, Italy More Info
Bergamo , 24127, Italy
Milano , 20133, Italy More Info
Napoli , 80131, Italy More Info
Sunto-gun Shizuoka, 411-8, Japan More Info
Hwasun Gun Jeonranamdo, 58128, Korea, Republic of More Info
Goyang-si Kyonggi-do, 10408, Korea, Republic of
Seoul , 03722, Korea, Republic of More Info
Lima Muni Metro De Lima, Lima , Peru
Lima , 15082, Peru
Lima , 15087, Peru
Baguio City Benguet, 2600, Philippines More Info
Lisboa , 1099-, Portugal More Info
Porto , 4200-, Portugal More Info
București Bucuresti, 02234, Romania More Info
Cluj-Napoca Cluj, 40001, Romania More Info
Ufa Baskortostan, Respublika, 45005, Russian Federation
Kaluga Kaluzskaja Oblast, 24800, Russian Federation
Moscow Moskva, 10522, Russian Federation
Moscow Moskva, 12536, Russian Federation
Samara Samarskaya Oblast, 44303, Russian Federation
St. Petersburg Sankt-Peterburg, 19702, Russian Federation
St. Petersburg Sankt-Peterburg, 19775, Russian Federation
Ekaterinburg Sverdlovskaya Oblast, 62003, Russian Federation
Kazan Tatarstan, Respublika, 42002, Russian Federation
Taipei , 11259, Taiwan
Taoyuan , 33305, Taiwan
Istambul Istanbul, 34098, Turkey More Info
Istanbul , 34722, Turkey More Info
Izmir , 35360, Turkey More Info
Cambridge Cambridgeshire, CB2 0, United Kingdom More Info
London London, City Of, SW3 6, United Kingdom More Info
London London, City Of, W12 0, United Kingdom More Info
Nottingham Nottinghamshire, NG5 1, United Kingdom More Info
London Worcestershire, NW1 2, United Kingdom More Info
How clear is this clinincal trial information?